کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8474375 | 1550425 | 2015 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
TTCMG53LVPWsIVSsCEMSLVEFI/R - I / RMyocardial infarction - آنفارکتوس میوکاردangioplasty - آنژیوپلاستیMyocardial ischemia - ایسکمی میوکاردischemia–reperfusion - ایسکمی-رپرفیوژنnitro blue tetrazolium - تترازولیم نیترو آبیTriphenyltetrazolium chloride - ترفتhenyltetrazolium chlorideTUNEL - تونلLeft ventricular posterior wall thickness - ضخامت دیواره خلفی بطن چپleft ventricular ejection fraction - کسر خروجی بطن چپfractional shortening - کوتاه کردن کسری
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
بیولوژی سلول
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury](/preview/png/8474375.png)
چکیده انگلیسی
Ischemic heart disease is a leading cause of death in human population and protection of myocardial infarction (MI) associated with ischemia-reperfusion (I/R) remains a challenge. MG53 is an essential component of the cell membrane repair machinery that protects injury to the myocardium. We investigated the therapeutic value of using the recombinant human MG53 (rhMG53) protein for treatment of MI. Using Langendorff perfusion of isolated mouse heart, we found that I/R caused injury to cardiomyocytes and release of endogenous MG53 into the extracellular solution. rhMG53 protein was applied to the perfusion solution concentrated at injury sites on cardiomyocytes to facilitate cardioprotection. With rodent models of I/R-induced MI, we established the in vivo dosing range for rhMG53 in cardioprotection. Using a porcine model of angioplasty-induced MI, the cardioprotective effect of rhMG53 was evaluated. Intravenous administration of rhMG53, either prior to or post-ischemia, reduced infarct size and troponin I release in the porcine model when examined at 24Â h post-reperfusion. Echocardiogram and histological analyses revealed that the protective effects of rhMG53 observed following acute MI led to long-term improvement in cardiac structure and function in the porcine model when examined at 4Â weeks post-operation. Our study supports the concept that rhMG53 could have potential therapeutic value for treatment of MI in human patients with ischemic heart diseases.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Molecular and Cellular Cardiology - Volume 80, March 2015, Pages 10-19
Journal: Journal of Molecular and Cellular Cardiology - Volume 80, March 2015, Pages 10-19
نویسندگان
Jianxun Liu, Hua Zhu, Yongqiu Zheng, Zhaobin Xu, Lei Li, Tao Tan, Ki Ho Park, Jincai Hou, Cuixiang Zhang, Dan Li, Ran Li, Zhenguo Liu, Noah Weisleder, Desheng Zhu, Peihui Lin, Jianjie Ma,